Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16315843 | 0.88 | MEN1 (0.47) | EPHX2CA1CA2TDP1CYP3A4 | |
| SCHEMBL3703562 | 0.88 | MEN1 (0.47) | EPHX2CA1CA2TDP1CYP3A4 | |
| SCHEMBL15084748 | 0.84 | TDP1 (0.41) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL31298558 | 0.84 | MEN1 (0.48) | EPHX2CA1CA2TDP1CYP3A4 | |
| SCHEMBL31296192 | 0.84 | TDP1 (0.51) | EPHX2CA1CA2TDP1CYP3A4 | |
| SCHEMBL21293834 | 0.84 | TDP1 (0.51) | EPHX2CA1CA2TDP1GLP1R | |
| SCHEMBL3486237 | 0.83 | TDP1 (0.43) | EPHX2CA1CA2TDP1CYP3A4 | |
| SCHEMBL14258504 | 0.82 | ADORA1 (0.37) | CA1CA2GLP1RMEN1GAA | |
| SCHEMBL20450590 | 0.82 | GLP1R (0.47) | TDP1GLP1RMEN1KMT2A | |
| SCHEMBL23601923 | 0.81 | CA1 (0.37) | EPHX2CA1CA2TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135306-B2 | Antibody-drug conjugates | CHO Pharma Inc. (TW) | 2021-10-05 | — | — | US | disclosed |
| US-20190328895-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2019-10-31 | — | — | US | disclosed |
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328895-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ADCY1, NEU1 | EPHX2 3578/4885CA1 402/4885CA2 510/4885 |
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ST6GAL1, PA2G4 | EPHX2 3956/4885CA1 469/4885CA2 552/4885 |
| US-11135306-B2 | Antibody-drug conjugates | CSGALNACT1, ST6GAL1, PA2G4 | EPHX2 3956/4885CA1 469/4885CA2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.